| Recruiting | SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment Parkinson Disease | — | 2025-08-27 |
| Recruiting | REal-life ON PARKinson's - ITaly (REONPARK-IT) Parkinson Disease | — | 2025-07-08 |
| Completed | eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. Parkinson Disease | Phase 4 | 2021-11-29 |
| Completed | OpicApone Sleep dISorder Parkinson Disease | Phase 4 | 2021-06-09 |
| Completed | Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study) Parkinson | Phase 3 | 2021-05-31 |
| Completed | OpiCapone Effect on Motor Fluctuations and pAiN Parkinson Disease | Phase 4 | 2021-02-25 |
| Completed | Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease Parkinson Disease | — | 2020-04-28 |
| Completed | Safety and Efficacy of BIA 5-1058 in PAH Pulmonary Arterial Hypertension | Phase 2 | 2019-06-26 |
| Completed | Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat) Pulmonary Arterial Hypertension | Phase 2 | 2019-06-03 |
| Completed | Anti-epileptogenic Effects of Eslicarbazepine Acetate Post Stroke Epilepsy | Phase 2 | 2019-05-29 |
| Completed | Relative Bioavailability and Bioequivalence of Opicapone Parkinson Disease | Phase 1 | 2019-03-19 |
| Completed | Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058 Cardiovascular Diseases | Phase 1 | 2019-01-22 |
| Completed | Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide Pulmonary Arterial Hypertension | Phase 1 | 2018-06-11 |
| Completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058 Cardiovascular Disease+Pulmonary Disease, Pulmonary Arterial Hypertension | Phase 1 | 2018-05-28 |
| Completed | Effect of BIA 5 1058 on Cardiac Repolarization Cardiovascular Disease, Pulmonary Arterial Hypertension, Heart Failure | Phase 1 | 2018-04-09 |
| Completed | Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil Pulmonary Arterial Hypertension | Phase 1 | 2018-03-22 |
| Completed | Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil Pulmonary Arterial Hypertension | Phase 1 | 2018-02-28 |
| Completed | Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics Pulmonary Arterial Hypertension | Phase 1 | 2018-02-23 |
| Completed | Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OP Parkinson Disease | Phase 1 | 2018-02-20 |
| Completed | Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan Pulmonary Arterial Hypertension | Phase 1 | 2018-02-06 |
| Completed | Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone Parkinson Disease | Phase 1 | 2017-06-20 |
| Completed | Absorption, Distribution, Metabolism and Excretion of BIA 5-1058 Pulmonary Arterial Hypertension | Phase 1 | 2017-03-31 |
| Completed | Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067 Parkinson Disease | Phase 1 | 2017-01-27 |
| Completed | Bioequivalence of Two Different Sources of Eslicarbazepine Acetate Epilepsy | Phase 1 | 2016-12-03 |
| Completed | Efficacy and Safety of Opicapone in Clinical Practice Parkinson's Disease With Wearing-off Motor Fluctuations | Phase 4 | 2016-11-23 |
| Completed | Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures Epilepsy | Phase 3 | 2016-03-01 |
| Terminated | Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058 Pulmonary Arterial Hypertension | Phase 1 | 2015-10-12 |
| Completed | Effect of Food on BIA 5-1058 Pulmonary Arterial Hypertension | Phase 1 | 2015-07-20 |
| Completed | Effect of Food on Opicapone Parkinson Disease | Phase 1 | 2014-11-21 |
| Completed | Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers Parkinson's Disease | Phase 1 | 2014-03-01 |
| Completed | Effect of Opicapone at Steady State on Warfarin Pharmacokinetics Parkinson's Disease | Phase 1 | 2014-03-01 |
| Completed | Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers Parkinson | Phase 1 | 2014-03-01 |
| Completed | Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation Epilepsy | Phase 1 | 2014-02-01 |
| Completed | Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone Parkinson Disease | Phase 1 | 2014-02-01 |
| Completed | Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation Wi Epilepsy | Phase 2 | 2012-12-01 |
| Completed | Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA) Epilepsy | — | 2012-03-01 |
| Completed | The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics Parkinson's Disease (PD) | Phase 1 | 2011-09-01 |
| Completed | Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects Parkinson Disease | Phase 1 | 2011-05-01 |
| Completed | Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. Parkinson's Disease | Phase 3 | 2011-03-01 |
| Completed | Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Parkinson's Disease | Phase 3 | 2011-03-01 |
| Completed | An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion Parkinson's Disease (PD) | Phase 1 | 2011-03-01 |
| Completed | Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058. Hypertension and Chronic Heart Failure | Phase 1 | 2011-03-01 |
| Completed | Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Epilepsy | Phase 3 | 2010-12-01 |
| Terminated | Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain Painful Diabetic Neuropathy | Phase 3 | 2010-11-01 |
| Completed | Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate Epilepsy | Phase 1 | 2010-10-01 |
| Terminated | Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia Post Herpetic Neuralgia | Phase 3 | 2010-09-01 |
| Completed | Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizu Partial Epilepsy | Phase 2 | 2010-08-01 |
| Completed | Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women Parkinson Disease | Phase 1 | 2010-05-01 |
| Completed | Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients Epilepsy | Phase 3 | 2010-04-01 |
| Completed | Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment Parkinson's Disease | Phase 1 | 2010-03-01 |
| Completed | Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics Parkinson's Disease (PD) | Phase 1 | 2010-02-01 |
| Completed | Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients Parkinson's Disease | Phase 2 | 2010-02-01 |
| Completed | Effect of Rasagiline on BIA 9-1067 Pharmacokinetics Parkinson Disease | Phase 1 | 2009-11-01 |
| Completed | Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic Parkinson Disease | Phase 1 | 2009-11-01 |
| Completed | Effect of BIA 9-1067 on Rasagiline Pharmacokinetics Parkinson Disease | Phase 1 | 2009-11-01 |
| Completed | Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine Epilepsy | Phase 1 | 2009-07-01 |
| Completed | Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin Parkinson's Disease (PD) | Phase 1 | 2009-06-01 |
| Completed | Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Epilepsy | Phase 1 | 2009-06-01 |
| Completed | Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide Parkinson Disease | Phase 1 | 2009-06-01 |
| Completed | Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites Parkinson Disease | Phase 1 | 2009-05-01 |
| Completed | Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine Migraine | Phase 2 | 2009-04-01 |
| Completed | Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia Fibromyalgia | Phase 2 | 2009-04-01 |
| Completed | A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067 Parkinson's Disease | Phase 2 | 2009-04-01 |
| Completed | Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide Parkinson Disease | Phase 1 | 2009-03-01 |
| Completed | Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa Parkinson Disease | Phase 1 | 2009-03-01 |
| Completed | Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-do Parkinson's Disease (PD) | Phase 1 | 2009-01-01 |
| Completed | Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizur Partial Epilepsy | Phase 3 | 2008-12-02 |
| Completed | Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbaze Partial Epilepsy | Phase 1 | 2008-11-01 |
| Completed | Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Parkinson Disease | Phase 1 | 2008-10-01 |
| Completed | Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a S Parkinson's Disease (PD) | Phase 1 | 2008-10-01 |
| Completed | Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a S Parkinson's Disease (PD) | Phase 1 | 2008-09-01 |
| Completed | Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-do Parkinson's Disease (PD) | Phase 1 | 2008-09-01 |
| Completed | Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites Hypertension, Congestive Heart Failure | Phase 1 | 2008-09-01 |
| Completed | Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contrace Partial Epilepsy | Phase 1 | 2008-09-01 |
| Completed | Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453 Hypertension | Phase 1 | 2008-07-15 |
| Completed | Bioavailability Study of BIA 5-453 Hypertension, Congestive Heart Failure | Phase 1 | 2008-07-15 |
| Completed | Pharmacokinetics of BIA 5-453 and Its Metabolites Hypertension, Chronic Heart Failure | Phase 1 | 2008-06-13 |
| Completed | Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules Parkinson | Phase 1 | 2008-05-01 |
| Completed | Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067 Parkinson's Disease (PD) | Phase 1 | 2008-04-01 |
| Completed | Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children Partial Epilepsy in Children and Adolescents | Phase 3 | 2007-12-07 |
| Completed | Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia Postherpetic Neuralgia | Phase 2 | 2007-11-01 |
| Completed | Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy Painful Diabetic Neuropathy | Phase 2 | 2007-11-01 |
| Completed | A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects Parkinson Disease | Phase 1 | 2007-10-01 |
| Completed | Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers Epilepsy | Phase 1 | 2007-10-01 |
| Completed | Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers Neuropathic Pain | Phase 1 | 2007-10-01 |
| Completed | Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function Epilepsy | Phase 1 | 2007-09-01 |
| Completed | Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453 Hypertension, Chronic Heart Failure | Phase 1 | 2007-09-01 |
| Completed | Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453 Hypertension, Chronic Heart Failure | Phase 1 | 2007-05-01 |
| Completed | Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formu Epilepsy | Phase 1 | 2007-05-01 |
| Completed | Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate Epilepsy | Phase 1 | 2007-05-01 |
| Completed | Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization Epilepsy | Phase 1 | 2007-03-01 |
| Completed | A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate Epilepsy | Phase 1 | 2007-01-01 |
| Completed | Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin. Epilepsy | Phase 1 | 2007-01-01 |
| Completed | A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Ad Epilepsy | Phase 1 | 2006-12-01 |
| Completed | Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine. Epilepsy | Phase 1 | 2006-11-01 |
| Completed | Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon Parkinson Disease | Phase 2 | 2006-09-26 |
| Completed | Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin Healthy | Phase 1 | 2006-09-01 |
| Completed | Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazid Parkinson Disease | Phase 1 | 2006-07-17 |
| Completed | Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine Epilepsy | Phase 1 | 2006-06-01 |
| Completed | Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics Parkinson Disease | Phase 1 | 2006-04-26 |
| Completed | Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disord Bipolar I Disorder | Phase 2 | 2006-03-01 |
| Terminated | Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I D BIPOLAR I DISORDER | Phase 2 | 2006-02-01 |
| Completed | Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects Parkinson Disease | Phase 1 | 2006-01-24 |
| Completed | Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites Parkinson's Disease | Phase 1 | 2006-01-01 |
| Completed | Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I D Bipolar I Disorder | Phase 2 | 2005-12-01 |
| Completed | Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa Parkinson's Disease | Phase 1 | 2005-09-01 |
| Completed | Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide Parkinson's Disease (PD) | Phase 1 | 2005-09-01 |
| Completed | Pharmacokinetics, Efficacy and Tolerability of BIA 2-093 Epilepsy | Phase 2 | 2005-06-01 |
| Completed | Effect of Food on BIA 6-512 (Trans-resveratrol) Parkinson Disease | Phase 1 | 2005-05-23 |
| Completed | Tolerability and Steady-state Pharmacokinetics of BIA 6-512 Parkinson Disease | Phase 1 | 2005-05-11 |
| Completed | An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 Epilepsy | Phase 1 | 2005-05-01 |
| Completed | Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive. Epilepsy | Phase 1 | 2005-03-01 |
| Completed | An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 Epilepsy | Phase 1 | 2005-03-01 |
| Completed | Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and Parkinson's Disease (PD) | Phase 2 | 2005-03-01 |
| Completed | Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy Partial Epilepsy | Phase 3 | 2004-12-01 |
| Completed | Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics Parkinson Disease | Phase 1 | 2004-11-03 |
| Completed | A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA Epilepsy | Phase 1 | 2004-10-01 |
| Completed | Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures Refractory Partial Epilepsy | Phase 3 | 2004-07-01 |
| Completed | Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epileps Partial Epilepsy | Phase 3 | 2004-07-01 |
| Completed | Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effe Parkinson Disease | Phase 1 | 2004-05-04 |
| Completed | Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of Epilepsy | Phase 1 | 2004-02-01 |
| Completed | Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers Epilepsy | Phase 1 | 2003-10-01 |
| Terminated | The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients Epilepsy | Phase 1 | 2002-11-01 |
| Completed | Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites Epilepsy | Phase 1 | 2002-06-01 |
| Completed | The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin Epilepsy | Phase 1 | 2002-05-01 |
| Completed | The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin Epilepsy | Phase 1 | 2002-05-01 |
| Completed | A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093 Epilepsy | Phase 2 | 2002-04-01 |
| Completed | Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volun Epilepsy | Phase 1 | 2002-03-01 |
| Completed | The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093 Epilepsy | Phase 1 | 2001-09-01 |
| Completed | Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3- Parkinson's Disease | Phase 1 | 2001-09-01 |
| Completed | Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose Parkinson's Disease | Phase 1 | 2001-04-01 |
| Completed | Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose Parkinson's Disease | Phase 1 | 2001-04-01 |
| Completed | A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerabi Epilepsy | Phase 1 | 2001-02-01 |
| Completed | Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA Parkinson's Disease | Phase 1 | 2000-09-01 |
| Completed | A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolera Epilepsy | Phase 1 | 2000-07-01 |
| Completed | Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202 Parkinson's Disease | Phase 1 | 2000-04-01 |